Table 1.
Baseline characteristics for patients conditioned with PG-free MEL (Evomela®) and PG-solubilized MEL (Alkeran®).
| PG-free MEL (Evomela®) n=216 |
PG-solubilized MEL (Alkeran®) n=200 |
P | |
|---|---|---|---|
| Age at Diagnosis, median (range) | 61 (30–75) | 60 (27–76) | 0.85 |
| Male, n (%) | 132 (61) | 116 (58) | 0.55 |
| Type of Myeloma, n (%) | 0.10 | ||
| IgG | 119 (55) | 109 (55) | |
| IgA | 46 (21) | 38 (19) | |
| Light chain | 50 (23) | 45 (23) | |
| Other | 1 (1) | 8 (4) | |
| ISS at diagnosis, n (%) | 0.92 | ||
| I | 57 (26) | 56 (28) | |
| II | 61 (28) | 51 (26) | |
| III | 52 (24) | 51 (26) | |
| Missing data | 46 (21) | 42 (21) | |
| FISH cytogenetics, n (%) | 0.45 | ||
| Standard risk | 131 (61) | 132 (66) | |
| High risk | 55 (25) | 47 (24) | |
| Missing data | 30 (14) | 21 (11) | |
| Induction regimen, n (%) | 0.29 | ||
| Triplet* | 138 (64) | 123 (62) | |
| Doublet† | 5 (2) | 12 (6) | |
| Other | 3 (1) | 2 (1) | |
| Multiple regimens prior to ASCT | 70 (32) | 63 (32) | |
| Duration of Induction, (months), median (IQR) | 4 (3–6) | 4 (3.25–6) | 0.34 |
| Age at ASCT, median (range) | 62 (31–75) | 61 (29–77) | 0.76 |
| Time from ASCT from diagnosis, (months), median (IQR) | 6 (5–10) | 6 (5–9) | 0.92 |
| Serum Creatinine prior to ASCT (mg/dL), median (IQR) | 1 (0.8–1.2) | 1 (0.8–1.2) | 0.51 |
| Disease status prior to ASCT, n (%) | 0.31 | ||
| Stable disease or Progression | 21 (10) | 26 (13) | |
| PR | 72 (33) | 77 (39) | |
| VGPR | 83 (38) | 61 (31) | |
| CR | 17 (8) | 11 (6) | |
| sCR | 23 (11) | 25 (13) | |
| Melphalan dose, n (%) | 0.10 | ||
| 200 mg/m2 | 161 (75) | 164 (82) | |
| Reduced-dose (e.g. 140 mg/m2) | 27 (13) | 22 (11) | |
| Other (e.g. +bortezomib) | 28 (13) | 14 (7) | |
*
Triplet regimens included a proteasome inhibitor (bortezomib, carfilzomib, or ixazomib), dexamethasone, and either an immunomodulatory agent (thalidomide or lenalidomide) or cyclophosphamide.
†
Doublet regimens included either bortezomib or lenalidomide, and dexamethasone.